|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Clinical Care/Education/Nutrition |
Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure
1 Institute of Health Economics, Edmonton, Alberta, Canada
2 Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada
3 Division of General Internal Medicine, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
4 Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
Address correspondence and reprint requests to Dr. Jeffrey A. Johnson, #1200, 10405 Jasper Ave., Edmonton, AB, Canada T5J 3N4. E-mail: jeff.johnson{at}ualberta.ca
OBJECTIVE—Metformin is considered contraindicated in patients with heart failure because of concerns over lactic acidosis, despite increasing evidence of potential benefit. The aim of this study was to evaluate the association between metformin and clinical outcomes in patients with heart failure and type 2 diabetes.
RESEARCH DESIGN AND METHODS—Using the Saskatchewan Health databases, 12,272 new users of oral antidiabetic agents were identified between the years 1991 and 1996. Subjects with incident heart failure (n = 1,833) were identified through administrative records based on ICD-9 code 428 and grouped according to antidiabetic therapy: metformin monotherapy (n = 208), sulfonylurea monotherapy (n = 773), or combination therapy (n = 852). Multivariate Cox proportional hazards models were used to assess differences in all-cause mortality, all-cause hospitalization, and the combination (i.e., all-cause hospitalization or mortality).
RESULTS—Average age of subjects was 72 years, 57% were male, and average follow-up was 2.5 ± 2.0 (SD) years. Compared with sulfonylurea therapy, fewer deaths occurred in subjects receiving metformin: 404 (52%) for sulfonylurea monotherapy versus 69 (33%) for metformin monotherapy (hazard ratio [HR] 0.70 [95% CI 0.54–0.91]) and 263 (31%) for combination therapy (0.61 [0.52–0.72]). A reduction in deaths or hospitalizations was also observed: 658 (85%) for sulfonylurea monotherapy versus 160 (77%) for metformin monotherapy (0.83 [0.70–0.99]) and 681 (80%) for combination therapy (0.86 [0.77–0.96]). There was no difference in time to first hospitalization between study groups.
CONCLUSIONS—Metformin, alone or in combination, in subjects with heart failure and type 2 diabetes was associated with lower morbidity and mortality compared with sulfonylurea monotherapy.
Abbreviations: CDS, chronic disease score
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
Find additional patient-related information at:
Related Article:
- Metformin and Heart Failure: Innocent until proven guilty
- Silvio E. Inzucchi
Diabetes Care 2005 28: 2585-2587.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  M. R. MacDonald, M. C. Petrie, N. M. Hawkins, J. R. Petrie, M. Fisher, R. McKelvie, D. Aguilar, H. Krum, and J. J.V. McMurray Diabetes, left ventricular systolic dysfunction, and chronic heart failure Eur. Heart J., May 2, 2008; 29(10): 1224 - 1240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Peter, A Cox, and M Evans Management of diabetes in cardiovascular patients Heart, March 1, 2008; 94(3): 369 - 375. [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Inzucchi and D. K. McGuire New Drugs for the Treatment of Diabetes: Part II: Incretin-Based Therapy and Beyond Circulation, January 29, 2008; 117(4): 574 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Erdmann and R. G. Wilcox Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure Eur. Heart J., January 1, 2008; 29(1): 12 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Inzucchi The Stealth Label Change DOC News, December 1, 2007; 4(12): 2 - 3. [Full Text]
|
|
|
|
 |
|
 S. E. Inzucchi, F. A. Masoudi, and D. K. McGuire Metformin in Heart Failure Diabetes Care, December 1, 2007; 30(12): e129 - e129. [Full Text] [PDF]
|
|
|
|
|
|
E. Erdmann, B. Charbonnel, R. G. Wilcox, A. M. Skene, M. Massi-Benedetti, J. Yates, M. Tan, R. Spanheimer, E. Standl, J. A. Dormandy, et al. Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease: Data from the PROactive Study (PROactive 08) Diabetes Care, November 1, 2007; 30(11): 2773 - 2778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Johnstone, T. J. Marrie, D. T. Eurich, and S. R. Majumdar Effect of Pneumococcal Vaccination in Hospitalized Adults With Community-Acquired Pneumonia Arch Intern Med, October 8, 2007; 167(18): 1938 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A A Tahrani, G I Varughese, J H Scarpello, and F W F Hanna Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ, September 8, 2007; 335(7618): 508 - 512. [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. H. Kahler, M. Rajan, G. G. Rhoads, M. M. Safford, K. Demissie, S.-E. Lu, and L. M. Pogach Impact of Oral Antihyperglycemic Therapy on All-Cause Mortality Among Patients With Diabetes in the Veterans Health Administration Diabetes Care, July 1, 2007; 30(7): 1689 - 1693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Roberts and G. J Ryan The Safety of Metformin in Heart Failure Ann. Pharmacother., April 1, 2007; 41(4): 642 - 646. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R Majumdar, F. A McAlister, D. T Eurich, R. S Padwal, and T. J Marrie Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study BMJ, November 11, 2006; 333(7576): 999 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Is It Safe to Use Metformin in CHF Patients? Journal Watch Cardiology, November 4, 2005; 2005(1104): 5 - 5. [Full Text]
|
|
|
|
 |
|
 Is It Safe to Use Metformin in CHF Patients? Journal Watch (General), October 28, 2005; 2005(1028): 4 - 4. [Full Text]
|
|
|
|
|
|
R. I. Misbin Evaluating the Safety of Diabetes Drugs: Perspective of a Food and Drug Administration insider Diabetes Care, October 1, 2005; 28(10): 2573 - 2576. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Inzucchi Metformin and Heart Failure: Innocent until proven guilty Diabetes Care, October 1, 2005; 28(10): 2585 - 2587. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |